Abstract Resmetirom is a liver-directed, thyroid hormone receptor-β (THR-β)-selective agonist approved for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis. Disposition in rats and dogs was qualitatively similar to that observed in humans, with high concentrations observed in the liver, kidney, and caecum. The primary circulating metabolite, MGL-3623 (M1), was disproportionate in humans and formed predominantly via CYP2C8.
